Authors
Kristin Mersmann, Martin Metzenmacher, Gregor Zaun, Marcel Wiesweg, Filiz Oezkan, Jane Winantea, Christian Taube, Dirk Theegarten, Martin Schuler, Lale Umutlu, Servet Bölükbas, Fabian Doerr, Daniel Messiha, Marcel Opitz, Wilfried Ee Eberhardt, Johannes Wienker
Published in
Frontiers in oncology. Volume 16. Pages 1886848. Epub Sep 21, 2026.
Abstract
Pulmonary embolism (PE) at initial diagnosis and during first-line systemic treatment is clinically relevant in patients with lung cancer. However, real-world incidence of subclinical PE is not well established.
Retrospective single-center analysis of patients at least 18 years old with non-small-cell lung cancer (NSCLC) or small-cell lung cancer (SCLC) who received first-line/induction systemic therapy. All patients underwent contrast-enhanced computed tomography (CT) of the thorax with bolus tracking for PE detection. Treatment response was assessed by restaging at weeks 6 and 12 after treatment initiation.
A total of 373 patients treated between 2019 and 2022 were included (261 NSCLC, 112 SCLC; 179 women and 194 men; median age 66 years [range, 22 to 86]; median smoking history 40 Pack Years [range, 0-150]). There was a predominance of locally advanced and metastatic disease (IB-IIB, n = 22; IIIA-C, n = 123; IVA-B, n = 228). Adenocarcinoma was the predominant histology among NSCLC cases (LUAD, n = 146), followed by squamous cell carcinoma and other NSCLC subtypes combined (n = 115); 112 patients had SCLC.PE was detected in 61/373 patients, of whom 58 (95%) had subclinical PE. In NSCLC, body-mass-index (BMI) was independently associated with occurrence of PE (OR = 1.111, p = 0.005), while central tumor localization (OR 5.637, p = 0.028) and vascular infiltration (OR 7.683, p = 0.010) were significantly associated with PE in SCLC. All patients with PE received anticoagulants according to national and international guidelines and no PE-related deaths occurred.
This single-center analysis demonstrates a high incidence of subclinical PE in newly diagnosed lung cancer patients and identifies clinical risk factors associated with PE development.
PMID:
42835926
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0